DACTOLISIB TOSYLATE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C30H23N5O.C7H8O3S
Molecular Weight	641.738
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(C=C1)S(O)(=O)=O.CN2C(=O)N(C3=C4C=C(C=CC4=NC=C23)C5=CC6=C(C=CC=C6)N=C5)C7=CC=C(C=C7)C(C)(C)C#N

InChI

InChIKey=FWURTHAUPVXZHW-UHFFFAOYSA-N

InChI=1S/C30H23N5O.C7H8O3S/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36;1-6-2-4-7(5-3-6)11(8,9)10/h4-17H,1-3H3;2-5H,1H3,(H,8,9,10)

HIDE SMILES / InChI

Molecular Formula	C7H8O3S
Molecular Weight	172.202
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C30H23N5O
Molecular Weight	469.5365
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://newdrugapprovals.org/2015/06/12/bez-235-nvp-bez235-dactolisib/
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800026094 https://www.ncbi.nlm.nih.gov/pubmed/18606717

Dactolisib is a dual inhibitor of phosphatidylinositol 3-kinase (P13K) and the downstream mammalian target of rapamycin (mTOR) by binding to the ATP-binding cleft of these enzymes (inhibitor of PI3K/Akt/mTOR cascade). It is being investigated as a possible anti-cancer cancer agent and drug against Influenza virus infections. Frequently reported adverse events included nausea, vomiting, diarrhoea, fatigue/asthenia, anaemia, and anorexia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serine/threonine-protein kinase mTOR 35 Target ID: CHEMBL2842 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19671762 \| https://www.ncbi.nlm.nih.gov/pubmed/18606717	Inhibitor 8504	21.0 nM [IC50]
PI3-kinase p110-alpha subunit 41 Target ID: CHEMBL4005 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19671762 \| https://www.ncbi.nlm.nih.gov/pubmed/18606717	Inhibitor 8504	4.0 nM [IC50]
PI3-kinase p110-beta subunit 31 Target ID: CHEMBL3145 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19671762 \| https://www.ncbi.nlm.nih.gov/pubmed/18606717	Inhibitor 8504	76.0 nM [IC50]
PI3-kinase p110-gamma subunit 32 Target ID: CHEMBL3267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19671762 \| https://www.ncbi.nlm.nih.gov/pubmed/18606717	Inhibitor 8504	7.0 nM [IC50]
PI3-kinase p110-delta subunit 43 Target ID: CHEMBL3130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19671762 \| https://www.ncbi.nlm.nih.gov/pubmed/18606717	Inhibitor 8504	5.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Pancreatic neuroendocrine tumors 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26851029	Primary	Phase II 1147	Unknown Approved Use Unknown
Breast cancer 432 Sources: http://adisinsight.springer.com/drugs/800026094 https://newdrugapprovals.org/2015/06/12/bez-235-nvp-bez235-dactolisib/	Primary	Phase II 1147	Unknown Approved Use Unknown
Influenza virus infections 34 Sources: http://adisinsight.springer.com/drugs/800026094	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
45.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28357727	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: EVEROLIMUS	EVEROLIMUS	DACTOLISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
101.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28357727	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: EVEROLIMUS	EVEROLIMUS	DACTOLISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
243 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28357727	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: EVEROLIMUS	EVEROLIMUS	DACTOLISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
468.5 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28357727	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: EVEROLIMUS	EVEROLIMUS	DACTOLISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
830.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28357727	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: EVEROLIMUS	EVEROLIMUS	DACTOLISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2167.3 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28357727	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: EVEROLIMUS	EVEROLIMUS	DACTOLISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28357727	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: EVEROLIMUS	EVEROLIMUS	DACTOLISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28357727	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: EVEROLIMUS	EVEROLIMUS	DACTOLISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28357727	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: EVEROLIMUS	EVEROLIMUS	DACTOLISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P008TV6	https://www.1pchem.com/search?query=1P008TV6
1PlusChem LLC	1P00GSBM	https://www.1pchem.com/search?query=1P00GSBM
A2B Chem	AH82402	http://a2bchem.com/prod/AH82402
AChemBlock	10290	http://www.achemblock.com/catalogsearch/result/?q=10290
AK Scientific	3486AH	https://aksci.com/item_detail.php?cat=3486AH
AK Scientific	X7430	https://aksci.com/item_detail.php?cat=X7430
AOBIOUS INC	AOB87110	http://aobious.com/aobious/search?search_query=AOB87110
ApexBio Technology	A8246	https://www.apexbt.com/catalogsearch/result/?q=A8246
AstaTech	41099	http://astatechinc.com/CPSResult.php?CRNO=41099
Axon MedChem	1281	https://www.axonmedchem.com/product/1281
BLD Pharm	BD629838	http://www.bldpharm.com/search/Search.html?keyword=BD629838
BOC Sciences	915019-65-7	http://www.bocsci.com/description.asp?cas=915019-65-7
Capot Chemical	16657	https://www.capotchem.com/search.do?q=16657
Cayman Chemical	10565	http://www.caymanchem.com/app/template/Product.vm/catalog/10565
Cayman Chemical	21185	http://www.caymanchem.com/app/template/Product.vm/catalog/21185
Chem Scene	CS-0080	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0080
Chem Scene	CS-0711	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0711
ChemShuttle	104794	https://www.chemshuttle.com/catalogsearch/result/?q=104794
eMolecules	114311714	https://orderbb.emolecules.com/search/#?query=114311714
eMolecules	18867474	https://orderbb.emolecules.com/search/#?query=18867474
eMolecules	44811472	https://orderbb.emolecules.com/search/#?query=44811472
Enamine	EN300-60135	https://www.enaminestore.com/catalog/EN300-60135
Excenen	EX-A404	http://www.excenen.com/searchresultlist.php?id=EX-A404
Exclusive Chemistry	2325	http://www.exchemistry.com/chem-catalog/product-2325.html
KeyOrganics	ES-0038	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=ES-0038
Lab Seeker	SC-50495	http://www.labseeker.com/search.php?keywords=SC-50495&category=0
LabSeeker	SC-50495	http://www.labseeker.com/search.php?keywords=SC-50495&category=0
Matrix Scientific	90884	http://www.matrixscientific.com/090884.html
mcule	MCULE-1407851271	https://mcule.com/MCULE-1407851271/
mcule	MCULE-7077128450	https://mcule.com/MCULE-7077128450/
MedChem Express	HY-15174	https://www.medchemexpress.com/search.html?q=HY-15174&ft=&fa=&fp=
MedChem Express	HY-50673	https://www.medchemexpress.com/search.html?q=HY-50673&ft=&fa=&fp=
Molnova	M16571	https://www.molnova.com/en/serch-list.html?keywords=M16571
MolPort	MolPort-005-737-784	https://www.molport.com/shop/molecule-link/MolPort-005-737-784
MolPort	MolPort-039-139-569	https://www.molport.com/shop/molecule-link/MolPort-039-139-569
MolPort	MolPort-044-561-823	https://www.molport.com/shop/molecule-link/MolPort-044-561-823
MuseChem	R043987	https://www.musechem.com/product/R043987.html
MuseChem	R066919	https://www.musechem.com/product/R066919.html
PI Chemicals	PI-42629	http://www.pipharm.com/catalog_products/PI-42629.html
Princeton BioMolecular Research	PBMR227128	http://www.princetonbio.com/order_online?common_id=PBMR227128
ShangHai Biochempartner	BCP000019	http://www.biochempartner.com/search_BCP000019
ShangHai Biochempartner	BCP00216	http://www.biochempartner.com/search_BCP00216
ShangHai Biochempartner	BCP16240	http://www.biochempartner.com/search_BCP16240
Synthonix	14315	https://synthonix.com/catalogsearch/result/?q=14315
TargetMol	T2235	https://www.targetmol.com/search?keyword=T2235
Tetrahedron	TS59327	http://www.thsci.com/search.do?q=TS59327
Toronto Research Chemicals	N925750	https://www.trc-canada.com/product-detail/?CatNum=N925750
Wonderchem	WD06ZUP	http://www.wonder-chem.com/search.html?text=WD06ZUP

PubMed

Title	Date	PubMed
Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition.	2015-07	25640480
Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.	2014-02-01	24041865
PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.	2013-08	23841834
Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.	2013-07-18	23651616
Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice.	2012-10	22949526
Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.	2012-07	22729845
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.	2012-04-10	22415236
Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.	2012	23029544
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.	2011-07	21633166
Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.	2011-06-01	21464613
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.	2011-06	21552262
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.	2011-04-15	21372221
The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.	2011-03	21498705
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.	2010-04	20129775
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.	2009-05-15	19435893
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.	2008-07	18606717

Patents

Sample Use Guides

In Vivo Use Guide

400 or 300 mg twice daily

Route of Administration: Oral

In Vitro Use Guide

IC50 doses of dactolisib for P3 and U87 glioma cells were established at 12.7 nM and 15.8 nM, respectively.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:04:56 GMT 2025` Edited by `admin` on `Mon Mar 31 18:04:56 GMT 2025`
Record UNII	U54GT9151S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DACTOLISIB TOSILATE

Preferred Name

English

DACTOLISIB TOSYLATE

Official Name

English

DACTOLISIB TOSYLATE [USAN]

Common Name

English

Dactolisib tosilate [WHO-DD]

Common Name

English

NVP-BEZ235-NX

Code

English

BENZENEACETONITRILE, 4-(2,3-DIHYDRO-3-METHYL-2-OXO-8-(3-QUINOLINYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)-.ALPHA.,.ALPHA.-DIMETHYL-, 4-METHYLBENZENESULFONATE (1:1)

Systematic Name

English

NVP-BEZ235-ANA

Code

English

Code System Code Type Description

PUBCHEM

49803145